Holen Sie sich die Stockscreener-App
3.57
0.00%
0.00
Handel nachbörslich:
3.64
0.07
+1.96%
Schlusskurs vom Vortag:
$3.57
Offen:
$3.6
24-Stunden-Volumen:
291.53K
Relative Volume:
2.89
Marktkapitalisierung:
$176.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.90M
KGV:
-6.7358
EPS:
-0.53
Netto-Cashflow:
$-19.80M
1W Leistung:
-9.62%
1M Leistung:
-14.39%
6M Leistung:
-35.21%
1J Leistung:
+27.50%
1-Tages-Spanne:
$3.475
$3.7484
1-Wochen-Bereich:
$3.475
$3.99
52-Wochen-Spanne:
$2.80
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Vergleichen Sie DMAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
3.57 | 176.68M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
DiaMedica Therapeutics Insiders Up US$4.1m On US$9.00m Investment - simplywall.st
Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
42,212 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Jane Street Group LLC - Defense World
Can DiaMedica Deliver A Breakthrough In Preeclampsia Treatment? - RTTNews
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 38.3% - Defense World
Lake Street Keeps Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
Northern Trust Corp Has $978,000 Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DMAC: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
DiaMedica Therapeutics’ (DMAC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright holds DiaMedica stock Buy rating, $10 target - Investing.com
H.C. Wainwright holds DiaMedica stock Buy rating, $10 target By Investing.com - Investing.com India
Transcript : DiaMedica Therapeutics Inc.Special Call - marketscreener.com
With 39% ownership, DiaMedica Therapeutics Inc. (NASDAQ:DMAC) insiders have a lot riding on the company's future - Yahoo Finance
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 - BioSpace
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 | DMAC Stock News - GuruFocus
14,581 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Balyasny Asset Management L.P. - Defense World
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on D - GuruFocus
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire
Research Analysts Offer Predictions for DMAC FY2025 Earnings - Defense World
Equities Analysts Offer Predictions for DMAC FY2029 Earnings - Defense World
DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds - MSN
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics reports annual meeting results By Investing.com - Investing.com Nigeria
DiaMedica Therapeutics reports annual meeting results - Investing.com
DiaMedica Elects Directors at Annual Meeting - TipRanks
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2025 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highligh - GuruFocus
DiaMedica Therapeutics Reports Q1 2025 Financials and Trial Progress - TipRanks
DiaMedica Therapeutics Announces Poster Presentation at European - GuruFocus
DiaMedica Therapeutics Announces Poster Presentation At European Stroke Organisation ConferenceESOC 2025 - marketscreener.com
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference -- ESOC 2025 | DMAC Stock News - GuruFocus
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025 - Business Wire
DiaMedica (DMAC) Awaits Key Phase 2 Study Results for Preeclamps - GuruFocus
Earnings call transcript: DiaMedica Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com India
Transcript : DiaMedica Therapeutics Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Earnings call transcript: DiaMedica Therapeutics Q1 2025 earnings beat expectations - Investing.com Australia
Barclays PLC Takes Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Raymond James Financial Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - BioSpace
DiaMedica Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
DiaMedica Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - TipRanks
DiaMedica Therapeutics Reports First Quarter 2025 Financial Resu - GuruFocus
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights | DMAC Stock News - GuruFocus
DiaMedica Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Susquehanna International Group LLP Grows Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - The AM Reporter
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May - BioSpace
How To Trade (DMAC) - news.stocktradersdaily.com
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Diamedica Therapeutics Inc-Aktie (DMAC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Giuffre Randall Michael | Director |
Feb 13 '25 |
Option Exercise |
2.56 |
17,000 |
43,570 |
392,412 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):